Ki Hyeong Lee
Institut Gustave Roussy
2 papers in the Anchorcite directory, published in 2017, cited 10,355 times in total.
ORCID profileResearch topics
- Lung Cancer Diagnosis and Treatment · 2 papers
- Lung Cancer Treatments and Mutations · 2 papers
- HER2/EGFR in Cancer Research · 1 paper
- Cancer Immunotherapy and Biomarkers · 1 paper
Frequent co-authors
- Byoung Chul Cho · 2 papers
- David Planchard · 2 papers
- Jhanelle E. Gray · 2 papers
- Jean‐Charles Soria · 1 paper
- Yuichiro Ohe · 1 paper
- Johan Vansteenkiste · 1 paper
- Thanyanan Reungwetwattana · 1 paper
- Busayamas Chewaskulyong · 1 paper
Papers
- Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung CancerNew England Journal of Medicine · 2017 · 5,640 citations
BACKGROUND: Osimertinib is an oral, third-generation, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively inhibits both EGFR-TKI-sensitizing and EGFR T790M resistance mutations. We compared osimertinib with standard EGFR-TKIs in patients with previously untreated, EGFR mutation-positive advanced non-small-cell…
- Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung CancerNew England Journal of Medicine · 2017 · 4,715 citations
BACKGROUND: Most patients with locally advanced, unresectable, non-small-cell lung cancer (NSCLC) have disease progression despite definitive chemoradiotherapy (chemotherapy plus concurrent radiation therapy). This phase 3 study compared the anti-programmed death ligand 1 antibody durvalumab as consolidation therapy with placebo in…
Metadata from OpenAlex (CC0).